Cargando…
Experience with Dopamine Agonists in the Treatment of Prolactinomas
The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cab...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Vilnius University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799005/ https://www.ncbi.nlm.nih.gov/pubmed/37733390 http://dx.doi.org/10.15388/Amed.2022.29.2.15 |
_version_ | 1784861025987723264 |
---|---|
author | Barabash, Nadiya Ye. Tykhonova, Tetiana M. |
author_facet | Barabash, Nadiya Ye. Tykhonova, Tetiana M. |
author_sort | Barabash, Nadiya Ye. |
collection | PubMed |
description | The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cabergoline demonstrated in this clinical case are reduction in the size of the adenoma from macro to micro, reverse development of chiasmal syndrome with restoration of visual functions, achievement and maintenance of the target level of prolactin. Besides the article focused on the possible development of primary and secondary resistance to dopamine analogues. One of such difficult clinical scenarios is illustrated by the clinical case of patient M., who was treated with different dopamine analogues with the development of secondary dopamine resistance. Along with described in literature possible mechanisms for its development in our patient we also suggest the role of prolonged inadequate therapy with dopamine agonists, when the dose of the drug was not properly adjusted, despite not reaching the target prolactin level. The literature considers several ways of optimization of treatment in resistant patients but despite of this fact it remains one of unresolved problems in the management of patients with hyperprolactinemia. |
format | Online Article Text |
id | pubmed-9799005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Vilnius University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97990052023-01-03 Experience with Dopamine Agonists in the Treatment of Prolactinomas Barabash, Nadiya Ye. Tykhonova, Tetiana M. Acta Med Litu Case Studies The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cabergoline demonstrated in this clinical case are reduction in the size of the adenoma from macro to micro, reverse development of chiasmal syndrome with restoration of visual functions, achievement and maintenance of the target level of prolactin. Besides the article focused on the possible development of primary and secondary resistance to dopamine analogues. One of such difficult clinical scenarios is illustrated by the clinical case of patient M., who was treated with different dopamine analogues with the development of secondary dopamine resistance. Along with described in literature possible mechanisms for its development in our patient we also suggest the role of prolonged inadequate therapy with dopamine agonists, when the dose of the drug was not properly adjusted, despite not reaching the target prolactin level. The literature considers several ways of optimization of treatment in resistant patients but despite of this fact it remains one of unresolved problems in the management of patients with hyperprolactinemia. Vilnius University Press 2022 2022-06-29 /pmc/articles/PMC9799005/ /pubmed/37733390 http://dx.doi.org/10.15388/Amed.2022.29.2.15 Text en Copyright © 2022 Nadiya Ye. Barabash, Tetiana М. Tykhonova. Published by Vilnius University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Case Studies Barabash, Nadiya Ye. Tykhonova, Tetiana M. Experience with Dopamine Agonists in the Treatment of Prolactinomas |
title | Experience with Dopamine Agonists in the Treatment of Prolactinomas |
title_full | Experience with Dopamine Agonists in the Treatment of Prolactinomas |
title_fullStr | Experience with Dopamine Agonists in the Treatment of Prolactinomas |
title_full_unstemmed | Experience with Dopamine Agonists in the Treatment of Prolactinomas |
title_short | Experience with Dopamine Agonists in the Treatment of Prolactinomas |
title_sort | experience with dopamine agonists in the treatment of prolactinomas |
topic | Case Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799005/ https://www.ncbi.nlm.nih.gov/pubmed/37733390 http://dx.doi.org/10.15388/Amed.2022.29.2.15 |
work_keys_str_mv | AT barabashnadiyaye experiencewithdopamineagonistsinthetreatmentofprolactinomas AT tykhonovatetianam experiencewithdopamineagonistsinthetreatmentofprolactinomas |